The US government has asked a Delaware federal court to reverse a recent jury decision favoring Gilead in the parties’ long-running HIV drug patent battle.
The case traces back to a complaint filed in 2019 alleging Gilead’s growing HIV pre-exposure prophylaxis (PrEP) franchise benefited from the CDC’s “groundbreaking PrEP work” funded by “hundreds of millions of taxpayer dollars.” The pharma giant’s Truvada and Descovy were initially approved for the treatment of HIV in 2004 and 2016, respectively, but each won approvals years later in the preventive setting.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters